Seeking Alpha

Alnylam Pharmaceuticals (ALNY) announces a restructuring plan that will include a 33% reduction...

Alnylam Pharmaceuticals (ALNY) announces a restructuring plan that will include a 33% reduction in the size of its workforce, with the goal of focusing on drugs aimed at treating amyloidosis and hemophilia. Analysts estimate Alnylam's 2011 revenue fell 17%, and expect its 2012 revenue to decline another 26.3%. Shares are currently halted.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs